Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Stroke

Molecular markers could help predict stroke risk after TIA

Nature Reviews Neurology volume 11, page 3 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

Stroke is preceded by transient ischaemic attack (TIA) in almost 20% of patients. Mariona Jové and colleagues have now shown that low concentrations of a specific lysophosphatidylcholine in plasma might indicate an increased risk of stroke recurrence after TIA. Assessment of metabolomic markers in combination with conventional predictors of stroke could improve accuracy of risk predictions, and might also provide an opportunity for stroke prevention.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jové, M. et al. Metabolomics predicts stroke recurrence after transient ischemic attack. Neurology 10.1212/WNL.0000000000001093

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Molecular markers could help predict stroke risk after TIA. Nat Rev Neurol 11, 3 (2015). https://doi.org/10.1038/nrneurol.2014.244

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.244

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research